Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma

Frontiers in Bioscience - Elite

Volumn 3 E, Issue 4, 2011, Pages 1500-1508

  Talebian, Laleh ^a   Wu, Jia Yan ^a   Fischer, Dawn A ^a   Hill, John M ^a   Szczepiorkowski, Zbigniew M ^b   Ernstoff, Marc S ^b   Sentman, Charles L ^b   Meehan, Kenneth R ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

Author keywords

Effector cells; IL 2; Immune mobilization; Myeloma; NKG2D

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER CELL RECEPTOR NKG2D; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CONVALESCENCE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LEUKAPHERESIS; LEUKEMIA CELL LINE; LYMPHOCYTE; MULTIPLE MYELOMA; MYELOMA CELL; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN EXPRESSION; SECRETORY GRANULE; STEM CELL MOBILIZATION; UPREGULATION; IMMUNOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; LYMPHOCYTES; MULTIPLE MYELOMA;

EID: 80053608376     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Horowitz, M. M, Report on state of the art in blood and marrow transplantation. CIBMTR Newsletter, 7 (2002)
2. Porrata, L. F., M. A. Gertz, D. J. Inwards, M. R. Litzow, M. Q. Lacy, A. Tefferi, D. A. Gastineau, A. Dispenzieri, S. M. Ansell, I. N. Mcallef, S. M. Geyer & S. N. Markovic: Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood, 98, 579-85 (2001)
3. Porrata, L. F, M. R. Litzow, D. J. Inwards, D. A. Gastineau, S. B. Moore, A. A. Pineda, K. L. Bundy, D. J. Padley, D. Persky, S. M. Ansell, I. N. Mcallef & S. N. Markovic: Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant, 33, 291-8 (2004)
4. Porrata, L. F, M. A. Gertz, S. M Geyer, M R. Litzow, D. A. Gastineau, S. B. Moore, A. A. Pineda, K. L. Bundy, D. J. Padley, D. Persky, M. Q. Lacy, A. Dispenzien, D. S. Snow & S. N. Markovic: The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia, 18, 1085-92 (2004) (Pubitemid 38786967)
5. Bensinger, W., J. F. Di Persio & J. M. McCarty: Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant, 43, 181-95 (2009)
6. Kim, H, H. J. Sohn, S. Kim, J. S. Lee, W. K. Kim & C. Suh: Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant, 37, 1037-42 (2006)
7. Hiwase, D. K, S. Hiwase, M. Bailey, G. Bollard & A. P. Schwarer: Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant, 14, 116-24 (2008) (Pubitemid 350286748)
8. Gazitt, Y, Immunologic profiles of effector cells and peripheral blood stem cells mobilized with different hematopoietic growth factors. Stem Cells, 18, 390-8 (2000)
9. Cesana, C, C. Carlo-Stella, E. Regazzi, D. Garau, G. Sammarelli, C. Caramatti, A. Tabilio, L. Mangoni & V. Rizzoli: CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Bone Marrow Transplant, 21, 561-8 (1998) (Pubitemid 28138254)
10. Verma, U. N., B. Yankelevich, J. Hodgson & A. Mazumder: Effect of the in vivo priming regimen for peripheral blood stem cells (PBSC) mobilization on in vitro generation of cytotoxic effectors by IL-2 activation of PBSC in a murine model. Bone Marrow Transplant, 19, 265-73 (1997) (Pubitemid 27077484)
11. Meehan, K. R., L. Talebian, J. Wu, J. M. Hill, Z. M. Szczepiorkowski, C. L. Sentman & M. S. Ernstoff: Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected. Cytotherapy, 12, 1013-21 (2010)
12. Groh, V., R. Rhinehart, H. Secrist, S. Bauer, K. H. Grabstein & T. Spies: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A, 96, 6879-84 (1999) (Pubitemid 29274978)
13. Coudert, J. D. & W. Held: The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol, 16, 333-43 (2006) (Pubitemid 44311504)
14. Meehan, K. R., J. Wu, E. Bengtson, J. Hill, P. Ely, Z. Szczepiorkowski, M. Kendall & M. S. Ernstoff: Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma. Bone Marrow Transplant, 39, 695-703 (2007) (Pubitemid 46813586)
15. Meehan, K. R., J. Wu, S. M. Webber, A. Barber, Z. M. Szczepiorkowski & C. Sentman: Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy. Cytotherapy, 10, 30-7 (2008)
16. Meehan, K. R.: The NK Activating Receptor NKG2D on CD8+T cells Plays a Critical Role in Identifying and Killing Autologous Myeloma Cells (2011)
17. Wu, J. Y., M. S. Ernstoff, J. M. Hill, B. Cole & K. R. Meehan: Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Cytotherapy, 8, 141-8 (2006) (Pubitemid 43675200)
18. Gertz, M. A., S. K. Kumar, M. Q. Lacy, A. Dispenzieri, S. R. Hayman, F. K. Buadi, D. Dingli, D. A. Gastineau, J. L. Winters & M. R. Litzow: Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant, 43, 619-25 (2009)
19. Sosman, J. A., P. Stiff, S. M. Moss, P. Sorokin, B. Martone, R. Bayer, K. Van Besien, S. Devine, W. Stock, D. Peace, Y. Chen, C. Long, D. Gustin, M. Viana & R. Hoffman: Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing highdose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol, 19, 634-44 (2001) (Pubitemid 32120142)
20. De Gast, G. C., F. A. Vyth-Dreese, W. Nooijen, C. J. Van Den Bogaard, J. Sein, M. M. Holtkamp, G. A. Linthorst, J. W. Baars, J. H. Schornagel & S. Rodenhuis: Reinfusion of autologous lymphocytes with granulocytemacrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer. J Clin Oncol, 20. 58-64 (2002) (Pubitemid 34032596)
21. Hock, B. D., L. F. Haring, A. M. Ebbett, W. N. Patton & J. L. McKenzie: Differential effects of G-CSF mobilisation on dendritic cell subsets in normal allogeneic donors and patients undergoing autologous transplantation. Bone Marrow Transplant, 30, 733-40 (2002) (Pubitemid 36004300)
22. Porrata, L. F., M. R. Litzow, A. Tefferi, L. Letendre, S. Kumar, S. M. Geyer & S. N. Markovic: Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia, 16, 1311-8 (2002)
23. Barber, A., T. Zhang & C. L. Sentman: Immunotherapy with chimeric NKG2D receptors leads to long-term tumorfree survival and development of host antitumor immunity in murine ovarian cancer. J Immunol, 180, 72-8 (2008)
24. Barber, A., T. Zhang, C. J. Megli, J. Wu, K. R. Meehan & C. L. Sentman: Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol, 36, 1318-28 (2008)
25. Verneris, M. R., M. Karami, J. Baker, A. Jayaswal & R. S. Negrin: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood, 103, 3065-72 (2004) (Pubitemid 38451682)
26. Baker, J., M. R. Verneris, M. Ito, J. A. Shizuru & R. S. Negrin: Expansion of cytolytic CD8 (+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood, 97, 2923-31 (2001)
27. Eagle, R. A., J. A. Traherne, O. Ashiru, M. R. Wills & J. Trowsdale: Regulation of NKG2D ligand gene expression. Hum Immunol, 67, 159-69 (2006) (Pubitemid 43673921)
28. Lanca, T., D. V. Correia, C. F. Moita, H. Raquel, A. Neves-Costa, C. Ferreira, J. S. Ramalho, J. T. Barata, L. F. Moita, A. Q. Gomes & B. Silva-Santos: The MHC class Ib protein ULBP1 is a non-redundant determinant of leukemia/lymphoma susceptibility to {gamma}{delta} T-cell cytotoxicity. Blood
29. Diefenbach, A., J. K. Hsia, M. Y. Hsiung & D. H. Raulet: A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol, 33, 381-91 (2003) (Pubitemid 36267602)
30. Shi, J., G. J. Tricot, T. K. Garg, P. A. Malaviarachchi, S. M. Szmania, R. E. Kellum, B. Storrie, A. Mulder, J. D. Shaughnessy, Jr., B. Barlogie & F. Van Rhee: Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood, 111, 1309-17 (2008) (Pubitemid 351213417)